ReviewVaccines2023
Vaccines against Group B Coxsackieviruses and Their Importance.
Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Pathogens of the human central nervous system-the major viral pathogens.Journal of neurovirology · 2026Review
- Study on the inhibitory effect of geniposide on coxsackievirus and its mechanism.Frontiers in pharmacology · 2026Article
- Does Coxsackievirus B3 Require Autophagosome Formation for Replication? Evidence for an Autophagosome-Independent Mechanism: Insights into Its Limited Potential as a Therapeutic Target.Pharmaceuticals (Basel, Switzerland) · 2025Article
- A dual monoclonal antibody-based sandwich ELISA for detection of potent vaccine immunogen against Coxsackievirus B1.Virologica Sinica · 2025Article
- Review
- Identification of Drug Repurposing Candidates for Coxsackievirus B3 Infection in iPSC-Derived Brain-like Endothelial Cells.International journal of molecular sciences · 2025Article
- Enteroviruses Activate Cellular Innate Immune Responses Prior to Adaptive Immunity and Tropism Contributes to Severe Viral Pathogenesis.Microorganisms · 2025Review
- CircPTPN11 inhibits the replication of Coxsackievirus B5 through regulating the IFN-I pathway by targeting miR-152-3p/SIRPA axis.Virus research · 2024Article
- Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles.Emerging microbes & infections · 2024Article
- Human Primary Macrophages Can Transmit Coxsackie B4 Virus to Pancreatic Cells In Vitro.Journal of medical virology · 2024Article
- Enteroviruses: epidemic potential, challenges and opportunities with vaccines.Journal of biomedical science · 2024Review
- Coxsackievirus B3 HFMD animal models in Syrian hamster and rhesus monkey.Virologica Sinica · 2024Article
- Article
- The knowns and unknowns of cardiac autoimmunity in viral myocarditis.Reviews in medical virology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The group B coxsackieviruses (CVBs) exist in six serotypes (CVB1 to CVB6). Disease associations have been reported for most serotypes, and multiple serotypes can cause similar diseases. For example, CVB1, CVB3, and CVB5 are generally implicated in the causation of myocarditis, whereas CVB1 and CVB4 could accelerate the development of type 1 diabetes (T1D). Yet, no vaccines against these viruses are currently available. In this review, we have analyzed the attributes of experimentally tested vaccines and discussed their merits and demerits or limitations, as well as their impact in preventing infections, most importantly myocarditis and T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.